title: [Results of treatment with recombinant human growth hormone in children with growth retardation in end-stage renal disease].
abstract: The aim of the study was to estimate the results of recombinant human growth hormone (rhGH) treatment in children with end-stage renal disease (ESRD). 60 growth retarded children with ESRD (mean age 11.2 +/- 7.2 years) were treated with rhGH at a dose of 1-1.1 IU/kg/week. The time of observation was 24 months. Thirty children completed first year, 18--second year of treatment. The mean growth velocity prior to the treatment was 3.03 +/- 1.9, during first year of the study--7.52 +/- 2.42, during second year 6.68 +/- 2.87 cm/year. The negative correlation between growth velocity and patient's age (r = -0.39; p < 0.05) suggest the better growth results in younger children during rhGH treatment. The rhGH therapy is effective method of treatment in growth retarded children with ESRD. Side effects are rare.
authors: Katedra i Klinika Pediatrii i Nefrologii Akademii Medycznej w Warszawie.
authors: M
authors: M
authors: Sieniawska
authors: M
authors: M
authors: Pańczyk-Tomaszewska
authors: H
authors: H
authors: Ziółkowska
authors: A
authors: A
authors: Jedrzejowski
authors: B
authors: B
authors: Leszczyńska
authors: P
authors: P
authors: Dyras
authors: A
authors: A
authors: Kałuzyńska
authors: I
authors: I
authors: Makulska
authors: J A
authors: JA
authors: Pietrzyk
authors: J
authors: J
authors: Rubik
authors: G
authors: G
authors: Siteń
authors: J
authors: J
authors: Stachowski
authors: K
authors: K
authors: Szprynger
authors: A
authors: A
authors: Zurowska
authors: M
authors: M
authors: Roszkowska-Blaim
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005260:Female; D006130:Growth Disorders / Q000150:complications* / Q000188:drug therapy*; D019382:Human Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications*; D008297:Male; D016896:Treatment Outcome
chemical_list: D019382:Human Growth Hormone